These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34131876)

  • 1. Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration.
    Egilman A; Wallach JD; Puthumana J; Zhang AD; Schwartz JL; Ross JS
    J Gen Intern Med; 2021 Oct; 36(10):3281-3284. PubMed ID: 34131876
    [No Abstract]   [Full Text] [Related]  

  • 2. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.
    Naci H; Smalley KR; Kesselheim AS
    JAMA; 2017 Aug; 318(7):626-636. PubMed ID: 28810023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018.
    Wallach JD; Ramachandran R; Bruckner T; Ross JS
    JAMA Netw Open; 2021 Nov; 4(11):e2133601. PubMed ID: 34751764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval.
    Wallach JD; Zhang AD; Skydel JJ; Bartlett VL; Dhruva SS; Shah ND; Ross JS
    JAMA Netw Open; 2021 Nov; 4(11):e2133667. PubMed ID: 34751763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration : A Cohort Study.
    Tau N; Yahav D; Shepshelovich D
    Ann Intern Med; 2020 Sep; 173(6):445-449. PubMed ID: 32716700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020.
    Moneer O; Lee CC; Avorn J; Kesselheim AS
    JAMA Netw Open; 2021 Apr; 4(4):e218530. PubMed ID: 33929526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preapproval Promises to Voluntarily Withdraw FDA-Approved Drugs.
    Fernandez Lynch H; Sachs RE
    JAMA; 2022 Dec; 328(24):2392-2393. PubMed ID: 36480185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is having more preapproval data the best way to assure drug safety?
    Garber AM
    Health Aff (Millwood); 2008; 27(5):w371-3. PubMed ID: 18682442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018.
    Omae K; Onishi A; Sahker E; Furukawa TA
    JAMA Netw Open; 2022 Sep; 5(9):e2230973. PubMed ID: 36083581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Fate of FDA Postapproval Studies.
    Woloshin S; Schwartz LM; White B; Moore TJ
    N Engl J Med; 2017 Sep; 377(12):1114-1117. PubMed ID: 28930510
    [No Abstract]   [Full Text] [Related]  

  • 12. Food and Drug Administration regulation and evaluation of vaccines.
    Marshall V; Baylor NW
    Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of antibiotic drugs in food animals: comparison of findings from preapproval studies and postapproval experience in the United States with safety information in published literature.
    Modric T; Modric S; Murphy MJ; Bright SJ; Shults S
    Vet Clin North Am Food Anim Pract; 2011 Jul; 27(2):389-405, ix. PubMed ID: 21575776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of Clinical Trials for the US Food and Drug Administration Accelerated Approval and Subsequent Confirmatory Trials: Implications for Drug Approval in Japan.
    Mamiya H; Narukawa M
    Biol Pharm Bull; 2024; 47(7):1345-1349. PubMed ID: 39048356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA.
    Mofid S; Bolislis WR; Kühler TC
    Clin Ther; 2022 Feb; 44(2):306-322. PubMed ID: 35074209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
    J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
    Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
    Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. US Food and Drug Administration-Mandated Postmarketing Studies for High-risk Cardiovascular Devices Approved 2015-2019.
    Hidano D; Dhruva SS; Redberg RF
    JAMA Intern Med; 2022 May; 182(5):556-558. PubMed ID: 35286367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?
    Wesevich A; Ratain MJ
    JAMA Oncol; 2023 Nov; 9(11):1489-1490. PubMed ID: 37651126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):243-246. PubMed ID: 29871507
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.